Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Trends Immunol. Author manuscript; available in PMC 2016 July 1.
Published in final edited form as:
PMCID: PMC4603374

Harnessing nanoparticles for immune modulation


Recent approaches using nanoparticles engineered for immune regulation have yielded promising results in preclinical models of disease. The number of nanoparticle therapies is growing, fueled by innovations in nanotechnology and advances in understanding of the underlying pathogenesis of immune-mediated diseases. In particular, recent mechanistic insight into the ways in which nanoparticles interact with the mononuclear phagocyte system and impact its function during homeostasis and inflammation have highlighted the potential of nanoparticle-based therapies for controlling severe inflammation while concurrently restoring peripheral immune tolerance in autoimmune disease. Here we review recent advances in nanoparticle-based approaches aimed at immune-modulation, and discuss these in the context of concepts in polymeric nanoparticle development, including particle modification, delivery and the factors associated with successful clinical deployment.


Nanotechnology is revolutionizing many aspects of modern medicine, including diagnostics and therapeutics [1,2]. The first nanoparticle (NP) therapy was approved by the FDA in 1989. Subsequently, numerous NP therapies have been approved, most of which have focused on optimizing the safety and pharmacokinetic properties of small-molecule agents and hormones [2,3]. More recently, our increasing knowledge of the cellular subsets and regulatory roles of various members of immune system, combined with the emergence of safe, biocompatible nanoparticle platforms, is catalyzing the development of complex, highly adaptable, and programmable NP therapies that are predicted to revolutionize the standard of care of numerous disorders. For example, NPs may be engineered to specifically target cells of the mononuclear phagocyte system (MPS) for the purposes of restoring peripheral immune tolerance or to regulate aberrant monocyte activities during severe inflammation [2,4-7]. Five-hundred-nanometer NPs with negative zeta potential can be harnessed to target circulating monocytes, reducing their potential for causing immune pathology in numerous experimental disease models including West Nile virus (WNV) encephalitis, myocardial infarction, and inflammatory bowel disease (IBD) [8]. The combination of such NPs with specific autoantigens can also be used to restore peripheral immune tolerance in autoimmune models including experimental autoimmune encephalitis (EAE) [5-7,9]. In addition, NPs maybe utilized to mop up extraneous circulating inflammatory mediators.

The functional outcome of NP immune modulation depends on numerous factors that are intrinsic to NPs, such as composition, size, and charge, as well as extrinsic factors such as route of administration. These concepts and how they relate to manipulating immune responses are the primary focus of this review.

Immunological considerations in therapeutic particle design and utilization

NP design

NPs are particles sized between 1 and 1500 nm. They can be made from almost any compound, including poly(amino acids), polysaccharides and poly(alpha-hydroxy acids) as well as non-degradable compounds such as gold, silver, carbon, iron, and silica. The ability to synthesize NPs from biocompatible and biodegradable polymers such as polylactide-co-glycolide (PLGA) has revolutionized the use of NPs in the field of immune modulatory therapeutics and this will be the focus here. NPs can be engineered to deliver, alone or in any combination, small-molecule drugs (including immune suppressants and chemotherapeutic agents), proteins (hormones and antibodies), peptides (for vaccine or immune tolerance purposes), DNA (as part of gene therapy approaches), miRNAs, and even machinery to target clustered regularly interspaced short palindromic repeat (CRISPR) components for gene-editing purposes. It is now clear that the physiochemical characteristics of unadorned NPs can also alter immune responses independently of any associated active pharmaceutical ingredient [8].

A primary function of NPs involves the delivery of a specific cargo and numerous methods have been developed due to the challenge associated with the efficiency of encapsulation and the properties of this cargo. A straight-forward approach is to chemically conjugate the desired active molecule to the particle. Peptide antigens have been chemically conjugated to NPs using 1-ethyl-3-(3-dimethy-laminopropyl)carbodiimide (EDC or ECDI) [6,9], which attaches the amine on the target to a carboxylic acid on the particle. Various chemistries, such as Click chemistry or Michael-type addition, are available and their use is based on the chemical groups within the polymer and on the cargo molecule. Alternatively, the active molecule can be incorporated into the particle directly. Using PLGA to exemplify the approach, if the cargo is either soluble in an organic solvent or stable in a crystalline form when dispersed in an organic solvent [10], the encapsulation can be accomplished using a water/oil single-emulsion method. For delivery of water-soluble molecules, these are incorporated into polymeric NPs using a water–oil–water double-emulsion method [11]. For the double-emulsion method, the aqueous drug is initially dispersed within the dissolved polymer solution and then a second emulsion is formed with an aqueous solution containing an emulsifying agent.

Size and shape

The downstream immunological outcome of NP therapy is strongly influenced by the mechanism of cellular uptake. NPs entering cells via pathways that allow access to the cytosol have different immune-modulating capabilities from those taken up via phagocytosis [12-14]. Size and shape influence biodistribution and the mechanism of particle uptake [15,16], but studies using a broad range of standard cell lines (HeLa, CHO, Caco-2, and MCF-7) and NPs (derived from gold, polystyrene, polymer, silicon, titanium, and iron oxide) show that the ideal size and shape for particle uptake depends on the cell type [16,17]. In non-phagocytic cell types, NP <100 nm diameter are most efficiently taken up via caveola- or clathrin-mediated processes [15,16]. For professional antigen-presenting cells (APCs) such as macrophages and dendritic cells (DCs), uptake is impacted more by shape than size, with spherical NPs having more favorable uptake kinetics than rod-shaped NPs, irrespective of NP size [18]. Targeting NPs to phagocytes is a critical aspect of any therapy attempting to manipulate the immune response and is discussed further below.

Size also affects NP toxicity [19]. Nanoparticles <100 nm in diameter tend to interact with cellular organelles, including the mitochondria and nucleus, and these interactions can trigger cellular respiratory and gene toxicity in cells [20]. This risk is reduced with increasing NP size, presumably because larger NPs tend to initiate phagocytosis, which effectively isolates particles from the more sensitive cytoplasmic environment.


NP charge is a dynamic physicochemical characteristic, with the particle microenvironment, including the protein corona, all capable of altering the surface charge of NPs. Generally speaking, NP charge can be modified by increasing the number of carboxyl (negative charge) or amine (positive charge) groups on the surface of the NP. Studies using different NP charges have clearly shown that this factor influences both uptake mechanisms and down-stream immune outcomes. For instance, relative to anionic particles, cationic NPs appear to be taken up more readily via clathrin-mediated processes [21]. Furthermore, positively charged antigen-loaded NPs are significantly more effective at stimulating Th1 responses after either intradermal or mucosal (pulmonary) inoculation, whereas anionic particles stimulate T and B cell responses poorly under similar conditions [22,23]. The ability of cationic particles to stimulate Th1 responses has been associated with preferential DC uptake of such particles and the propensity of cationic particles to regulate positive costimulatory molecules [24]. However, cationic NPs may also alter mitochondrial and endoplasmic reticulum function, triggering the production of reactive oxygen species and proinflammatory cytokines, as well as cell death [25-27]. These events may underlie the adjuvant effects of cationic NPs, but attempts to harness this phenomenon clinically will need to address the consequences of any off-target toxicities.

Anionic NPs, by contrast, have been associated with little to no toxicity [20]. Furthermore, NPs with a charge below −30 mV have been found to have anti-inflammatory properties and when combined with antigen can induce antigen-specific immune tolerance [6,8,9]. This phenomenon is associated with the ability specifically to target scavenger receptors such as MARCO on monocytes and macrophages [6,8,9].

Stiffness and fluidity

Stiffness also affects the biological impact of NPs. NPs made of rigid materials may be associated with increased potential for embolism, while flexible polymer-based NPs that can more easily deform may gain better access to tissues during the complex vascular changes associated with inflammation. The fluidity of NPs, too, affects the ability of antigen-loaded NP to stimulate immune responses. Thus, intramuscular, solid-phase, antigen-containing liposome immunization elicits a more robust Th1/Th17 response than similarly administered fluid-phase liposomes [28]. The stimulatory ability of solid-phase particles is proposed to result from the formation of an immobilized antigen particle depot, similar to that observed for traditional oil-in-water emulsions and aluminum adjuvants [29,30]. This results in a prolonged supply of antigen for APCs and is also associated with upregulation of positive costimulatory molecules such as CD80, which support efficient T cell priming [28]. By contrast, intramuscularly injected fluid-state liposomes are rapidly removed, do not appear to stimulate positive costimulation, and are much less capable of stimulating a T cell response [28]. Whether the intramuscular fluid liposome–antigen combination induced peripheral immune tolerance was not tested, but intraperitoneal (IP) administration of fluid OVA-decorated liposomes can induce antigen-specific IgE non-responsiveness [31,32]. While this was argued to occur in a T cell-independent fashion, the increased levels of IgG after IP administration suggest immune deviation [33]. Notwith-standing this, these findings highlight the importance of understanding the contribution of fluidity and stiffness in NP-mediated manipulation of immune outcomes.

Factors associated with particle opsonization

Based on in vitro studies with fetal bovine serum, a protein corona forms around NPs in a two-step process. In the first step, high-affinity proteins rapidly bind to NPs to form a primary corona. In the second step, proteins of lower affinity bind either directly to the NP or to the proteins in the primary corona forming a secondary corona [34-37]. Constituents of the protein corona are thus inevitably impacted by the protein content of the serum and thus by the homeostatic or immune responses that regulate it. The above studies show that proteins with high abundance, such as albumin, comprise a significant proportion of the primary corona [34,38]. However, we have found that NPs with different charges bind significant amounts of less-abundant proteins in the plasma of WNV-infected animals [39].

In vivo the formation of a protein corona has been associated with little to no impact on NP delivery and function [8]. However, proteins binding to NPs could feasibly alter NP charge or mask functional groups important for NP targeting to certain receptors and/or enhance clearance of NPs by phagocytes [27,36,40]. Therefore, NP engineering efforts have focused on the development of techniques to reduce this phenomenon [41]. Many of these methods have been informed by experience gained from increasing the half-life of biologic therapies [42]. Commonly used processes include coating the NP’s surface with polymeric ethylene glycol (PEG) or its low molecular weight derivative polyethylene oxide (PEO) [43]. PEG increases surface hydrophilicity, resulting in improved circulating NP half-life due to reduced serum protein binding [43]. Un-like PEG, the use of PEO to develop ‘stealth’ NPs has been associated with potential toxicity issues. Like, PEG, PEO forms a mushroom- or brush-like configuration on the surface of NPs. Unlike PEG, however, PEO may activate the C1q-dependent complement pathway in its mushroom-like configuration, whereas the brush-like configuration can trigger the lectin-specific complement cascade [44]. Interestingly, although NP coatings may prolong NP serum half-life, cells of the MPS still appear to be involved in the primary clearance mechanism for intravenously infused NPs [43]. Although these observations highlight the possibilities for modulating NP surfaces to reduce opsonization events, they also serve as a potent warning that such changes can dramatically alter the biocompatibility of NPs.

NP administration route and organ localization

The biodistribution of NPs has been examined in many studies, but widely varying conditions have resulted in diverse datasets, often making specific conclusions difficult (Figure 1). For example, studies often fail to perfuse animals before tissue examination [45-49], making it difficult to discriminate between NPs in the bloodstream and NPs adherent to the endothelium or NPs that have gained access to the organ parenchyma. In non-perfused animals after intravenous (IV) NP administration, the high intravenous NP content in organs with large blood volumes makes assessment of biodistribution extremely difficult by most modalities and the accurate evaluation of NP interactions with specific cells in the tissue virtually impossible (D.R. Getts and N.J.C. King, unpublished).

Figure 1
Size and administration heavily impact the biodistribution of nanoparticles (NPs). The underlying immunological niche of each physiological site determines the downstream outcome of NP administration. For example, the skin is associated with immune induction, ...

NPs introduced into the body are generally perceived as foreign and the innate immune mechanisms that protect against invasive pathogens usually recognize, remove, and potentially degrade NPs rapidly. Subcutaneously administered NP are exposed to a highly specialized immune environment containing numerous migratory antigen-presenting subsets as well as relatively sedentary structural cells such as fibroblasts, all in the context of the local lymphatic drainage system. Similar to mucosal and intra-muscular sites, the lymphatics carry APCs to local lymph nodes where processing and containment of antigenic material occurs. Small particles (<200 nm) may drain freely from subcutaneous, muscular, and even mucosal sites of application to local lymph nodes [50]. However, particles >200 nm in size must be phagocytosed by local or blood-derived phagocytes before transport to the draining lymph nodes. Both freely draining and APC-associated NPs arrive in the subcapsular sinus of the lymph node. This region is rich in CD169-expressing macrophages [51], which in the spleen are important for the coordination of CD8+ dendritic cells and their stimulation of effective CD4+ and CD8+ T cell responses against invading pathogens [52]. Subcutaneous delivery of NPs is very effective for stimulating immune responses to numerous T and B cell antigens [50,53]. Once there, NPs rarely escape the lymph node, which generally contains foreign antigenic material to limit the spread of invasive pathogens. Only ultrafine NPs (30 nm in size) seem to circumvent this sequestration [54]. However, this size of NP is associated with increased potential for oncogenesis and toxicity.

Intravenously administered NPs theoretically have access to the entire body; however, their biodistribution is strongly influenced by size [48,55,56]. For example, intra-venously infused nanoparticles of diameter <5 nm can pass through the glomeruli and be detected in the urine [57]. Except where vascular integrity is disrupted, intra-venously delivered NPs >100 nm in diameter cannot cross endothelial barriers such as the blood–brain barrier or the endothelial lining of the heart, reproductive organs, and gastrointestinal tract [48,55,56]. These particles, irrespective of surface modifications, are predominately engulfed by circulating monocytes and cells of the MPS that line the fenestrated endothelium of the spleen and liver. The latter cells are essential for the daily filtering and phagocytosis of apoptotic cells and other debris from the blood [48,55,56] and these cells are critically associated with the maintenance of peripheral tolerance. The delivery of NPs via the IV route, in the absence of adjuvant, promotes immune tolerance and provides an avenue to modulate circulating inflammatory monocytes [6,8,9].

It is clear that the route of administration of NPs impacts both the organ distribution and the possible down-stream immune outcomes. This point has been acknowledged by the FDA immunogenicity assessment guidance on therapeutic protein therapies [58]. In this document the authors note that, relative to other administration routes, IV administration of proteins and protein-containing therapies is associated with reduced risk of immune stimulation and cytokine-release syndrome-like events [58].

Therapeutic immune manipulation: beyond vaccines

The potential for NPs to optimize vaccination has been examined extensively [2,59,60], as has the delivery of immune-suppressive agents by NPs [61,62]. This horizon has recently expanded to include the use of NPs to control immune pathology associated with severe inflammatory responses as well as in the restoration of peripheral immune tolerance. These novel avenues are discussed in greater detail below.

Addressing acute inflammatory responses with NPs

The innate immune response is essential for host survival. However, abnormal or overactive acute inflammatory responses can result in immune pathology. This can result from cytokine-release syndrome, such as that caused by some biological therapies, or from aberrant innate immune cell function associated with numerous infectious agents, including Ebola, influenza, flaviviruses, and MERS as well as associated syndromes such as acute encephalitis syndrome and severe acute respiratory syndrome (SARS) [63-65].

Removal of inflammatory mediators and specific toxins

Overproduction of cytokines and other inflammatory mediators is a common occurrence in poorly regulated immune responses [63-65]. This phenomenon can be severe or life-threatening if left unchecked. Treatment options are limited, with large-dose steroids the most frequently prescribed treatment. Recently, extracorporeal filters such as the cytosorb, used during dialysis, have been effective in sepsis [66,67]. However, this treatment modality is limited by the need for expensive dialysis machinery. NPs may revolutionize this approach as NPs may be engineered for in vivo use, with surface modifications or the attachment of antibodies or other moieties, to bind specific toxins and/or proteins before being safely digested by liver and spleen phagocytes. In recent rodent proof-of-concept studies, infused highly negatively charged ‘immune-modifying NPs’ (IMPs) can absorb certain blood proteins, including S100 family and heat shock proteins, before finally being removed and destroyed by cells of the mononuclear phagocyte system [8,39,68]. Furthermore, this mechanism may also be used to capture and concentrate certain circulating proteins. IMPs have been shown to bind Annexin 1. The accumulation of Annexin 1 and its presentation to particular leukocyte subsets can have broad immune outcomes. For example, Annexin 1-loaded NPs may reduce neutrophils via induction of apoptosis [69] and/or promote T cell activation [70].

Targeting inflammatory myeloid cells

In humans, monocytes express CD14, from CD14lo to CD14hi, as well as CD115 (the CSF-1 receptor) and the integrin CD11b. As the major monocyte population in normal blood in humans, CD14hi CD16 defines ‘classical’ or inflammatory monocytes [71]. In mice, this population is identified by its Ly6Chi CD43lo CCR2+ CX3CR1lo phenotype [72,73]. By contrast, a much smaller, CD14lo, CD16hi ‘nonclassical’ or patrolling monocyte subset comprises some 10% of blood monocytes in humans and is defined as Ly6Clo CD43hi CCR2lo CX3CR1hi in mice [72,73]. CD14hi CD16hi and Ly6Chi CD43hi subsets define an intermediate group in humans and mice, respectively. Comparative RNA profiling suggests that human intermediate monocytes are functionally closest to mouse classical monocytes [74,75]. Work in many areas, including infectious disease, hypoxia, autoimmunity, and cancer, shows a definable wave of inflammatory monocyte recruitment into inflamed tissues expressing CCL2 and other chemokines. Once in the target tissue, these cells may differentiate into different effector cells, including DCs, macrophages, and even cells with a microglial phenotype [4,76], depending on the prevailing soluble factor milieu. In some cases these cells have important housekeeping functions (i.e., to digest and clear tissue debris before tissue remodelling); however, in many cases they express high levels of NO via induced NOS2 expression, as well as increased levels of NADPH oxidase, cathepsins, and myeloperoxidase, all of which may demonstrably contribute to further tissue damage in numerous conditions, including experimental autoimmune encephalomyelitis, myocardial infarction, and viral encephalitis [8,77,78]. Such monocyte management has recently emerged as a unique potential treatment modality to limit damage associated with the acute phase of inflammation in numerous disease indications.

The circulation serves as the primary conduit for monocytes to travel from the bone marrow/spleen throughout the body to sites of inflammation, making these highly susceptible to being targeted via intravenously administered NP. One approach involving the combination of siRNA with liposomes has shown some promise in animal models [78]. However, we have recently shown that NPs derived from a broad array of biodegradable and non-degradable compounds and molecules, without traditional active pharmaceutical ingredients (APIs) or other additional immune-stimulating agents, are able, through targeting of precise scavenger receptors, to reduce circulating inflammatory monocytes. Specifically, IMPs (i.e., NPs with a highly negative surface charge) bind with high specificity to inflammatory monocytes, marking them for sequestration by the spleen and thereby preventing migration to sites of inflammation and subsequent differentiation and participation in pathogenic immune responses [8]. Sequestered monocytes either undergo caspase-3-mediated apoptosis or differentiate into CD11b+ CD11c+ CD103+ DCs [8,39]. While the role of these CD103+ CD11b+ DCs remains to be completely defined, IMP treatment is associated with the expansion of a short-lived, TIM3-expressing regulatory T cell (Treg) population [39] (D.R. Getts et al., unpublished). The emergence and subsequent disappearance of these Tregs correlates with treatment efficacy in EAE models [39]. This monocyte management approach is effective in numerous models of inflammation (Table 1) and Phase 1/2 clinical studies are planned for 2016.

Table 1
IMP efficacy in severe inflammation models.

NPs for immune tolerance

Autoimmunity results from the breakdown of peripheral tolerance, an active immunological process that usually controls self-reactive T and B cells. The ‘Holy Grail’ of autoimmune therapy is the restoration or induction of robust peripheral immune tolerance in only those cells causing disease. The use of apoptotic cells to induce tolerance was uncovered originally in 1979 [79] and has shown promise in an early clinical study [80], However, the use of cells has numerous manufacturing, cost, and patient accessibility issues. The serendipitous discovery that negatively charged NPs target specific scavenger receptors and localize to the same regions of the spleen, similar to apoptotic cells, catalyzed the development of a synthetic cell replacement that could carry antigen for immune tolerance induction [6,8,81]. Subsequently, several NP-based approaches for the induction of immune tolerance that function via alternative mechanisms have emerged. Some focus on harnessing the natural capabilities of NPs to deliver antigen in a tolerogenic fashion, while other approaches deliver antigen combined with small-molecule immune suppressants or target aryl hydrocarbon receptors to change DC phenotype [5-7,9]. Below is a brief discussion of the mechanisms through which NPs have been shown to induce tolerance, with a focus on harnessing NP delivery of antigen without additional immune suppressants or modulating agents.

NP development for tolerance

The induction of immune tolerance using NPs, at least in rodent models, depends on several factors. First and foremost, NPs have to be loaded with the correct antigen and targeted to APCs capable of regulating T cell function concurrently with supporting the induction and/or expansion of Tregs.

The ability of antigen-loaded NPs to inactivate, with exquisite specificity, autoreactive T cell clones depends on the delivery of antigens that, when processed by APCs, will be directly recognized by autoreactive T cells [5-7]. The primary hurdle for antigen-specific tolerance approaches remains the identification of disease-associated antigens and their epitopes. Thus, in many autoimmune diseases, the epitopes associated with disease remain to be defined. Identification is further complicated in multiple sclerosis (MS), for example, by the fact that the appropriate target antigen may change over time due to epitope spreading. Nevertheless, in some disorders, including celiac disease, MS, and type 1 diabetes, numerous antigens have been identified [80,82-84]. Another potential strategy, which both harnesses the natural mechanisms that may have initiated autoimmunity and obviates the need for knowing the precise epitopes, may be the use of full-length proteins. Encapsulation of full-length proteins may allow host APCs to liberate numerous non-defined epitopes from autoantigens, similar to the process that presumably underlies the initiation of the disease.

The appropriate targeting and subsequent tolerogenic stimulation of certain populations of APCs is crucial for immune tolerance induction. Incorrect targeting can result in immune stimulation. For example, antigen-loaded NPs that are designed to target CD40, DEC205, or CD11c induce robust production of IL-12 and type 2 interferon as well as CD8+ T cell proliferation [85], whereas particles that target MARCO+ macrophages in the liver and spleen induce tolerance [6]. This highlights the fact that APC populations are not created equal, with some populations better equipped for tolerance induction and others equipped for immune induction. Germane to this, splenic and liver macrophage populations express numerous scavenger receptors, which during homeostasis play an important role in the recognition and recycling of dying leukocytes, red blood cells, and other debris on a daily basis [86-88]. Importantly, these activities occur without triggering inflammation or breaking peripheral immune tolerance. Tolerogenic IMPs (TIMPs) were designed to take advantage of the MARCO-targeting ability of highly negatively charged NPs [8,89]. The intravenous administration of antigen-encapsulated IMPs results in biodistribution similar to that of apoptotic debris [6,81], with particles homing to MARCO+ macrophages in the liver and spleen (Figure 2) [6,8,9,81]. More importantly, one course of TIMPs results in tolerance induction through T cell anergy and the parallel induction of Tregs [90]. This mechanism has subsequently been shown to be applicable to the induction of long-lived tolerance in numerous Th1-, Th17-, and even Th2-mediated rodent disease models (Table 2).

Figure 2
Proposed mechanism of action tolerance induction using toleragenic immune modifying nanoparticles (TIMPs). The induction of tolerance using TIMPs requires that the antigen-loaded particles must be delivered intravenously. The particles themselves are ...
Table 2
NP immune tolerance platform efficacy.

The inherent immunological behavior of lymph nodes, especially the phenomenon historically known as ‘lymph node shutdown’ makes it very difficult to target liver and spleen populations using non-intravenous routes of administration. In the context of TIMPs, IP administration results in only partial tolerance, while subcutaneous and oral delivery fail to induce regulation [5,6,9]. In some cases, subcutaneous administration can even result in sensitization and/or disease exacerbation [5,6,9]. The lymph nodes appear to be devoid of inherently ‘tolerogenic’ macrophage populations. This may be unsurprising, since most epithelial surfaces are consistently being challenged by opportunistic and other pathogens and, as a potential defense mechanism, epithelial and lymph node APC populations tend to express higher levels of costimulatory molecules than APCs elsewhere (D.R. Getts et al., unpublished). There have been attempts to utilize NPs that combine antigen and immune-suppressive agents such as rapamycin to alter DC phenotype in vivo and potentially induce tolerance [5,6,9]. Rapamycin has been known for over two decades to have ‘tolerogenic’ effects when combined with antigen [91,92] and the adoptive transfer of rapamycin-treated DCs can promote the long-term survival of skin grafts in rodent transplant recipients [93]. In the context of NPs, Haddadi and colleagues showed that rapamycin-loaded PLGA NPs preferentially bound to DCs and induced an immature ‘tolerogenic’ phenotype [61]. More recently, Maldonado and colleagues showed that biweekly subcutaneous injections of pegylated PLGA rapamycin and OVA323–334 NPs significantly reduced the production of OVA-specific IgG [5]. However, it should be noted that, with repeated OVA exposure, titers were observed to increase over time in treated mice [5]. Using similar particles, although loaded with PLP139–151, the authors also showed that subcutaneous injection could reduce the incidence of EAE; however, unlike intravenous infusion, protection was not 100% [5,94]. Another strategy that focuses on altering DC phenotype is the administration of NPs that agonize the ligand-activated transcription factor aryl hydrocarbon receptor [7,95-97]. The activation of aryl hydrocarbon receptor on DCs supports their differentiation into tolerogenic APCs, which supports the expansion of Tregs [95-97]. Using the MOG35–55 or PLP39–151 EAE model, pegylated gold NPs loaded with the aryl hydrocarbon receptor agonist 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester and MOG35–55 or PLP39–151 were tested for their ability to ameliorate disease [7]. While not tested subcutaneously, weekly IP or IV administration of these NPs successfully resulted in disease management [7].

An alternative approach to delivering NP–antigen cocktails to APCs involves the direct targeting of specific T cell populations associated with disease. For example, it has been shown that polyclonal Tregs can be expanded using NPs coated with leukemia inhibitory factor [98]. A more antigen-specific approach includes using polymeric or monomeric peptide MHC (pMHC), which may selectively delete T cells expressing the cognate T cell receptor that recognizes the pMHC complex. These have shown efficacy in experimental models of transplantation and type 1 diabetes; however, clinical translation is complicated by the requirement of having exquisite knowledge of each autoreactive epitope [99,100]. Nevertheless, the field is rapidily progressing toward clinical translations of NP use for treatment of various disease states using the inherent properties of NPs to direct antigen uptake to particular APC subsets for the induction of immunity or tolerance.

Concluding remarks

The use of NPs as immune-regulating agents has only recently emerged and many unanswered questions remain. In the future, the development of novel biocompatible polymers, as well as our increased understanding of the precise interplay between the physiochemical characteristics of NPs and their associated downstream immune interactions, is likely to result in further expansion of the field. In the next 3–5 years, several clinical studies are expected to begin testing the ability of highly negatively charged PLGA NPs to reduce severe inflammation in myocardial infarction and acute encephalitis syndrome [8]. Furthermore, evidence suggests that clinical testing of NP tolerance platforms in areas such as pemphigus vulgaris, types 1 diabetes, MS and even celiac disease is likely to occur in the next 2–3 years (; Moving forward, questions surrounding the most appropriate NP formulation and safety will need to be addressed. Further barriers, such as antigen identification in the context of autoimmunity treatments, also remain. At the very least, these studies will inform future NP approaches. If successful, however, these therapies will revolutionize the treatment of many diseases and place NP-based therapies at the forefront of immune-modulating therapeutics.


1. Laroui H, et al. Nanotechnology in diagnostics and therapeutics for gastrointestinal disorders. Dig Liver Dis. 2013;45:995–1002. [PMC free article] [PubMed]
2. Smith DM, et al. Applications of nanotechnology for immunology. Nat Rev Immunol. 2013;13:592–605. [PubMed]
3. Preiss MR, et al. Bionanotechnology: Biological Self-assembly and its Applications. Horizon Scientific Press; 2013.
4. Getts DR, et al. Ly6c+ ‘inflammatory monocytes’ are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J Exp Med. 2008;205:2319–2337. [PMC free article] [PubMed]
5. Maldonado RA, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A. 2015;112:E156–E165. [PubMed]
6. Getts DR, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol. 2012;30:1217–1224. [PMC free article] [PubMed]
7. Yeste A, et al. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2012;109:11270–11275. [PubMed]
8. Getts DR, et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med. 2014;6:219ra217. [PMC free article] [PubMed]
9. Hunter Z, et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano. 2014;8:2148–2160. [PMC free article] [PubMed]
10. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. 1998;16:153–157. [PubMed]
11. Whittlesey KJ, Shea LD. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp Neurol. 2004;190:1–16. [PubMed]
12. Mellman I. Endocytosis and antigen processing. Semin Immunol. 1990;2:229–237. [PubMed]
13. Davidson HW, et al. Endocytosis, intracellular trafficking, and processing of membrane IgG and monovalent antigen/membrane IgG complexes in B lymphocytes. J Immunol. 1990;144:4101–4109. [PubMed]
14. Harding CV, Unanue ER. Antigen processing and intracellular Ia. Possible roles of endocytosis and protein synthesis in Ia function. J Immunol. 1989;142:12–19. [PubMed]
15. Shang L, et al. Nanoparticle interactions with live cells: quantitative fluorescence microscopy of nanoparticle size effects. Beilstein J Nanotechnol. 2014;5:2388–2397. [PMC free article] [PubMed]
16. Shang L, et al. Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnol. 2014;12:5. [PMC free article] [PubMed]
17. Gratton SE, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105:11613–11618. [PubMed]
18. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A. 2006;103:4930–4934. [PubMed]
19. Adjei IM, et al. Nanoparticles: cellular uptake and cytotoxicity. Adv Exp Med Biol. 2014;811:73–91. [PubMed]
20. Park MV, et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials. 2011;32:9810–9817. [PubMed]
21. Harush-Frenkel O, et al. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun. 2007;353:26–32. [PubMed]
22. Fromen CA, et al. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci U S A. 2015;112:488–493. [PubMed]
23. Bal SM, et al. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine. 2011;29:1045–1052. [PubMed]
24. Koppolu B, Zaharoff DA. The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials. 2013;34:2359–2369. [PMC free article] [PubMed]
25. Hwang TL, et al. Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int J Nanomed. 2015;10:371–385. [PMC free article] [PubMed]
26. Chiu HW, et al. Cationic polystyrene nanospheres induce autophagic cell death through the induction of endoplasmic reticulum stress. Nanoscale. 2014;7:736–746. [PubMed]
27. Xia T, et al. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano. 2008;2:85–96. [PubMed]
28. Christensen D, et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release. 2012;160:468–476. [PubMed]
29. Munks MW, et al. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood. 2010;116:5191–5199. [PubMed]
30. Richards RL, et al. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol Cell Biol. 2004;82:531–538. [PubMed]
31. Nakano Y, et al. Surface-linked liposomal antigen induces IgE-selective unresponsiveness regardless of the lipid components of liposomes. Bioconjug Chem. 2001;12:391–395. [PubMed]
32. Uchida T. Surface-linked liposomal antigen induces IgE selective unresponsiveness in a T-cell independent fashion. Curr Drug Targets Immune Endocr Metab Disord. 2003;3:119–135. [PubMed]
33. Matsuoka T, et al. Allergen immunotherapy and tolerance. Allergol Int. 2013;62:403–413. [PubMed]
34. Fleischer CC, Payne CK. Nanoparticle–cell interactions: molecular structure of the protein corona and cellular outcomes. Acc Chem Res. 2014;47:2651–2659. [PMC free article] [PubMed]
35. Fleischer CC, Payne CK. Secondary structure of corona proteins determines the cell surface receptors used by nanoparticles. J Phys Chem B. 2014;118:14017–14026. [PMC free article] [PubMed]
36. Fleischer CC, et al. Cellular binding of anionic nanoparticles is inhibited by serum proteins independent of nanoparticle composition. Biomater Sci. 2013;1:975–982. [PMC free article] [PubMed]
37. Fleischer CC, Payne CK. Nanoparticle surface charge mediates the cellular receptors used by protein–nanoparticle complexes. J Phys Chem B. 2012;116:8901–8907. [PMC free article] [PubMed]
38. Walczyk D, et al. What the cell “sees” in bionanoscience. J Am Chem Soc. 2010;132:5761–5768. [PubMed]
39. King N, Getts D. Cour Pharmaceutical Development Company. Immune-modifying particles for the treatment of inflammation. WO2014160465.
40. Maffre P, et al. Effects of surface functionalization on the adsorption of human serum albumin onto nanoparticles – a fluorescence correlation spectroscopy study. Beilstein J Nanotechnol. 2014;5:2036–2047. [PMC free article] [PubMed]
41. Moghimi SM, et al. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318. [PubMed]
42. McDonnell T, et al. PEGylated drugs in rheumatology – why develop them and do they work? Rheumatology. 2014;53:391–396. [PMC free article] [PubMed]
43. Owens DE, III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93–102. [PubMed]
44. Hamad I, et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere–serum interface: implications for stealth nanoparticle engineering. ACS Nano. 2010;4:6629–6638. [PubMed]
45. Chawla R, et al. Polylactide-co-glycolide nanoparticles of antitubercular drugs: formulation, characterization and biodistribution studies. Ther Deliv. 2014;5:1247–1259. [PubMed]
46. Yu H, et al. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. J Control Release. 2014;205:89–97. [PubMed]
47. Bryant J, et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials. 2014;35:8887–8894. [PMC free article] [PubMed]
48. Alexis F, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515. [PMC free article] [PubMed]
49. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42:463–478. [PubMed]
50. Xiang SD, et al. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods. 2013;60:232–241. [PubMed]
51. Gray EE, et al. Subcapsular sinus macrophage fragmentation and CD169+ bleb acquisition by closely associated IL-17-committed innate-like lymphocytes. PLoS ONE. 2012;7:e38258. [PMC free article] [PubMed]
52. Backer R, et al. Effective coll-aboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc Natl Acad Sci U S A. 2010;107:216–221. [PubMed]
53. Mohanan D, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010;147:342–349. [PubMed]
54. Kourtis IC, et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE. 2013;8:e61646. [PMC free article] [PubMed]
55. Vinogradov SV, et al. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002;54:135–147. [PubMed]
56. Wong J, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev. 2008;60:939–954. [PubMed]
57. Choi HS, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165–1170. [PMC free article] [PubMed]
58. FDA. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. US Department of Health and Human Services; 2014.
59. Sharma R, et al. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities. Biotechnol Adv. 2014;33:64–79. [PubMed]
60. Zhao L, et al. Nanoparticle vaccines. Vaccine. 2014;32:327–337. [PubMed]
61. Haddadi A, et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A. 2008;84:885–898. [PubMed]
62. Guzman LA, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation. 1996;94:1441–1448. [PubMed]
63. Stebbings R, et al. Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol. 2009;20:673–677. [PubMed]
64. D’Elia RV, et al. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol. 2013;20:319–327. [PMC free article] [PubMed]
65. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013;8:411–440. [PubMed]
66. Honore PM, et al. Con: dialy- and continuous renal replacement (CRRT) trauma during renal replacement therapy: still under-recognized but on the way to better diagnostic understanding and prevention. Nephrol Dial Transplant. 2013;28:2723–2727. discussion 2727–2728. [PubMed]
67. Honore PM, et al. Newly designed CRRT membranes for sepsis and SIRS – a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59:99–106. [PubMed]
68. Cox DA. Effects of plasma components from naive and West Nile virus-infected mice on cellular uptake of immune modulating microparticles. Australasian Society for Immunology Annual Scientific Meeting; University of Sydney. 2014.
69. Vago JP, et al. Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis. J Leukoc Biol. 2012;92:249–258. [PubMed]
70. D’Acquisto F, et al. Annexin-1 modulates T-cell activation and differentiation. Blood. 2007;109:1095–1102. [PMC free article] [PubMed]
71. Ziegler-Heitbrock L. Monocyte subsets in man and other species. Cell Immunol. 2014;289:135–139. [PubMed]
72. Drevets DA, et al. The Ly-6Chigh monocyte subpopulation transports Listeria monocytogenes into the brain during systemic infection of mice. J Immunol. 2004;172:4418–4424. [PubMed]
73. Geissmann F, et al. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71–82. [PubMed]
74. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762–774. [PMC free article] [PubMed]
75. Shi L, et al. Genome-wide analysis of interferon regulatory factor I binding in primary human monocytes. Gene. 2011;487:21–28. [PMC free article] [PubMed]
76. Getts DR. Editorial to special issue: monocytes in homeostasis and disease. Cell Immunol. 2014;291:1–2. [PubMed]
77. Getts DR, et al. Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages. J Neuroinflamm. 2012;9:246. [PMC free article] [PubMed]
78. Majmudar MD, et al. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation. 2013;127:2038–2046. [PMC free article] [PubMed]
79. Miller SD, et al. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med. 1979;149:758–773. [PMC free article] [PubMed]
80. Lutterotti A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a Phase 1 trial in multiple sclerosis. Sci Transl Med. 2013;5:188ra175. [PMC free article] [PubMed]
81. Getts DR, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol. 2011;187:2405–2417. [PMC free article] [PubMed]
82. Chow IT, et al. Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PLoS ONE. 2014;9:e112882. [PMC free article] [PubMed]
83. Delong T, et al. Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunol Res. 2013;55:167–172. [PMC free article] [PubMed]
84. Sollid LM, et al. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics. 2012;64:455–460. [PMC free article] [PubMed]
85. Cruz LJ, et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study. J Control Release. 2014;192:209–218. [PubMed]
86. Bennett GD, Kay MM. Homeostatic removal of senescent murine erythrocytes by splenic macrophages. Exp Hematol. 1981;9:297–307. [PubMed]
87. Bratosin D, et al. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie. 1998;80:173–195. [PubMed]
88. Strydom N, Rankin SM. Regulation of circulating neutrophil numbers under homeostasis and in disease. J Innate Immun. 2013;5:304–314. [PubMed]
89. Chao Y, et al. Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. Bioconjug Chem. 2012;23:1003–1009. [PMC free article] [PubMed]
90. Getts DR, et al. Exploiting apoptosis for therapeutic tolerance induction. J Immunol. 2013;191:5341–5346. [PMC free article] [PubMed]
91. Chen H, et al. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. J Immunol. 1994;152:3107–3118. [PubMed]
92. Birsan T, et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation. 2003;75:2106–2113. [PubMed]
93. Horibe EK, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol. 2008;18:307–318. [PubMed]
94. Kishimoto TK, et al. Tolerogenic synthetic nanoparticles for the prevention of anti-drug antibodies. 3rd International Conference on Immune Tolerance; Elsevier; 2014.
95. Quintana FJ, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107:20768–20773. [PubMed]
96. Hauben E, et al. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood. 2008;112:1214–1222. [PubMed]
97. Nguyen NT, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A. 2010;107:19961–19966. [PubMed]
98. Park J, et al. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm. 2011;8:143–152. [PMC free article] [PubMed]
99. Maile R, et al. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol. 2001;167:3708–3714. [PubMed]
100. Serra P, Santamaria P. Nanoparticle-based autoimmune disease therapy. Clin Immunol. 2015 Published online February 19, 2015. [PubMed]
101. Prasad S, et al. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun. 2012;39:347–353. [PMC free article] [PubMed]
102. Smarr CB, et al. Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol. 2013;33:389–414. [PMC free article] [PubMed]
103. Smarr CB, et al. Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J Immunol. 2011;187:5090–5098. [PMC free article] [PubMed]
104. Wang S, et al. Transient B-cell depletion combined with apoptotic donor splenocytes induces xeno-specific T- and B-cell tolerance to islet xenografts. Diabetes. 2013;62:3143–3150. [PMC free article] [PubMed]